Exsure, the Bhubaneswar-based biotech startup, has raised ₹3 crore in a seed funding round led by Unicorn India Ventures.
The funds raised will be used to complete the non-clinical study with its exosome-based drug delivery vehicle and will also support Exsure’s global expansion plan with its in-house manufactured R&D products and promote Exosure, Leucosure, PlantExosure, and Dr. Berries.
In the coming 12 months, Exsure plans to non-clinical study and work on team building. The company also plans to present its data for CDSCO approval, strengthen the team size along with expanding its product marketing and sales at a global level.
Bhaskar Majumdar, Managing Partner, Unicorn India Ventures, said, “The fear of Big C is real not just for the patients but even their families. Exsure with its advancement in scientific tools, technology and cutting-edge medical research has built a powerful Exosome based drug that commits to staying at the forefront of advancement in therapeutics science. The funding accelerates Exsure’s mission to deploy solutions at a global level. We believe Exsure will not only continue to sustain its momentum but also grow due to its potential for transformative breakthroughs through its nano delivery platform. The company has witnessed remarkable progress in the last 12 months and has launched more innovative products. Hence, we believe the market opportunity is huge and the company has built the right momentum to capitalise on this segment.”
Swastika Paul, CSO and Co-founder, Exsure, said, “During our PhD journey, we witnessed the toxicity of the present-day chemotherapy drugs and how 13% of the in-treatment cancer patients die due to toxicity of the chemotherapy drugs. Exsure is on a mission to reduce the toxicity of the chemotherapy drugs and make them more targeted to the cancerous cells. Our vision is to empower millions of cancer patients around the world and improve their quality of life.”
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup working to reduce the side effects and toxicity of anti-cancer drugs by its patented exosomal drug-delivery platform that targets cancer and cancer stem cells.
With its technology, the company aims at reducing the toxic effects of chemotherapy and the chances of cancer relapse improving the quality of lives of patients suffering from cancer.
In the last 12 months, Exsure has initiated the non-clinical study in India in collaboration with a CRO and completed one of its milestones in the preclinical study using its patented technology.
The company also reported a 5 fold growth last fiscal year and is on track to service more than 50 clients this year with its R&D products, Exosure (3-in-1 exosome isolation reagent), Leucosure (PBMC isolation reagent) and PlantExosure (India’s 1st Plant exosome isolation reagent).
It has also been selected for the OIST Innovation Accelerator program in Japan for business expansion and conducting clinical trials.
